Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Merck
Mallinckrodt
Boehringer Ingelheim

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

See Plans and Pricing

« Back to Dashboard

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-11-19
Court District Court, D. New Jersey Date Terminated 2018-05-23
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Cathy L. Waldor
Parties ACTAVIS LLC; CHARLES E. LIPSEY; MYLAN INC.; MYLAN LABORATORIES LTD.; MYLAN PHARMACEUTICALS, INC.; PHV KAREN L. CARROLL; PROGENICS PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, INC.; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; WYETH LLC
Patents 6,559,158; 8,247,425; 8,420,663; 8,552,025; 8,822,490; 9,180,125
Attorneys ACTAVIS LLC; ALISSA MARIE PACCHIOLI; AMY DANIELLE LURIA; BRYAN C. DINER; CYMETRA MONIQUE WILLIAMS; ELVIN ESTEVES (Do not use or delete); HOWARD J. SCHWARTZ; J. BRUGH LOWER; JASON B. LATTIMORE; JONATHAN ROTENBERG; LAUREN BROPHY COOPER; LEIGH A. DECOTIIS; MICHAEL ANDREW HOLTMAN; MICHAEL LLOYD BINNS; TYLER DOH; WILLIAM P. DENI , JR.
Firms Aiston & Bird LLP; Critchley Kinum & Denoia LLC; Epstein Becker & Green, P.C.; Finnegan Henderson Farabow Garrett and Dunner; Goodwin Procter LLP, the New York Times Building; Howard J. Schwartz; Katten Muchin Rosenman LLP; Law Office of Jason B. Lattimore, Esq.; Leigh A. Decotiis; Parker Poe Adams & Bernstein LLP
Link to Docket External link to docket
Small Molecule Drugs cited in VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARMACEUTICALS, INC. (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 227 Stipulation Issues to be Presented at Trial as to U.S. Patent No. 8,552,025 by PROGENICS PHARMACEUTICALS, INC., SALIX… 2015 23 May 2018 2:15-cv-08180 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 234 Stipulation and Order issues to be presented at trial as to U.S. Patent No. 8,552,025. Signed by Judge Stanley R. Chesler on 3… 2015 23 May 2018 2:15-cv-08180 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 261 Motion in Limine and described in the Wyeth patents-in-suit (U.S. Patent Nos. 8,247,425, 8,420,663, 8,822,490 and 9,180,125…related to the prior art status of International Patent Application Publication No. WO 2008/019115 (“Shah… 2015 23 May 2018 2:15-cv-08180 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 300 Order on Motion for Summary Judgment affects [sic].” U.S. Patent No. 6,559,158. Plaintiffs do not contend that the ’025 patent covers a new use…of the relevant patents. Plaintiffs’ motion concerns claim 8 of United States Patent No. 8,552,025 (the… This is a Hatch-Waxman case involving a patent dispute regarding pharmaceuticals: the complaints…(the “’025 patent”). ’ Plaintiffs move for partial summary judgment on Defendants’ affirmative… 3. “Foss ’954” (Deni Dec. Ex. 3.) U.S. Patent No. 5,972,954 covers methods of use of External link to document
0000-00-00 321 Judgment infringement of claim 8 of U.S. Patent No. 8,552,025 (“the ’025 patent”) of invalidity due to obviousness…Plaintiffs’ claims of patent infringement against Defendants as to claim 8 of the ’025 patent, and of Defendants…Defendants. WHEREAS, this is an action for patent infringement having been brought by Plaintiffs …infringement of, inter alia, claim 8 of the ’025 patent with respect to Actavis’s Abbreviated New Drug …infringement of, inter alia, claim 8 of the ’025 patent with respect to Mylan’s ANDA Nos. 208592 and 208594 External link to document
0000-00-00 9 Amended Complaint United States Patent Nos. 8,247,425 (“the ’425 patent”); 8,420,663 (“the ’663 patent”); 8,552,025 (“…. 021964, the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent are listed in the FDA…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and the ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and the ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and the ’125 patent; 9. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.